Invention Grant
- Patent Title: Human anti-IL-33 neutralizing monoclonal antibody
-
Application No.: US15037998Application Date: 2014-12-26
-
Publication No.: US09725508B2Publication Date: 2017-08-08
- Inventor: Yasuhiro Fujino , Tsutomu Yoshikawa , Hiroshi Ochi
- Applicant: Mitsubishi Tanabe Pharma Corporation
- Applicant Address: JP Osaka
- Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee Address: JP Osaka
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: JP2013-270551 20131226; JP2014-078223 20140404
- International Application: PCT/JP2014/084695 WO 20141226
- International Announcement: WO2015/099175 WO 20150702
- Main IPC: C07K16/24
- IPC: C07K16/24 ; A61K39/395 ; A61K39/00

Abstract:
An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.
Public/Granted literature
- US09758578B2 Human anti-IL-33 neutralizing monoclonal antibody Public/Granted day:2017-09-12
Information query